2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment

EP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment

Back to course

Pdf Summary

The study investigates the real-world outcomes of U.S. Asian patients with EGFR-mutated stage IV non-small cell lung cancer (NSCLC) when treated with first-line osimertinib compared to first or second-generation tyrosine kinase inhibitors (early TKIs) or sequential treatment strategies. The focus is particularly on patients with the EGFR mutations ex19del or L858R, a demographic highlighted due to prior observations of differential overall survival (OS) outcomes in the FLAURA, GioTag, and UpSwinG studies.<br /><br />The single-institution retrospective study conducted at the NYU Perlmutter Cancer Center analyzed 139 Asian patients between 2010 and 2020. Patients were categorized based on received treatments: first-line osimertinib, early TKIs, and sequential treatment combining early TKIs followed by osimertinib. The study aimed to assess the three-year OS rates across different treatment modalities and genetic subtypes using Kaplan-Meier survival analysis and log-rank statistical tests.<br /><br />Key findings show that in patients with the ex19del mutation, those treated with first-line osimertinib had worse OS compared to those who received early TKIs or underwent sequential treatment. Notably, there was no OS advantage seen for first-line osimertinib in patients with the L858R mutation when compared to the other treatment strategies. This suggests potential variance in treatment efficacy based on EGFR mutation subtype, highlighting the importance of personalized treatment plans.<br /><br />The study acknowledges its limitations, such as its small cohort size and retrospective nature, stressing the necessity for further research. Specifically, larger cohort studies or prospective trials are recommended to explore alternative treatment methods, notably involving combination therapies, for Asian populations with EGFR-mutated NSCLC.

Asset Subtitle

Ying Liu

Meta Tag

Speaker Ying Liu

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

EGFR-mutated NSCLC

Asian patients

osimertinib

tyrosine kinase inhibitors

ex19del mutation

L858R mutation

overall survival

Kaplan-Meier analysis

personalized treatment

retrospective study